LDL Electronegativity- a novel determinant of mortality risk in ASCVD

There needs to be more data on Whether such alterations are associated with adverse outcomes in patients with a history of acute coronary syndromes ACS. These patients are at high cardiovascular risk.

The study design included 2619 patients who had a history of ACS. They assessed LDL electronegativity and lipidome.

The essential points of research design are:

• There was an association between LDL electronegativity changes and all-cause mortality at 30 days with aHR and one year with a notable association with cardiovascular mortality.
• LDL electronegativity superseded traditional risk factors.
• LDL electronegativity improves GRACE score performance.
• Enriched lipid species (L1 vs L5) were independently linked to the mortality risk.

They said altered LDL quality is a novel determinant of adverse outcomes in ACS patients.

We demonstrate for the first time that attenuated LDL electronegativity, as assessed by the L1-L5 ratio, unfavourably associates with all-cause and cardiovascular mortality after the index ACS, over and above the updated GRACE risk score, they said.

Electronegative properties of LDL particles are tightly linked to alterations in their lipidome and represent a novel determinant of mortality risk in patients with ACS.

https://www.atherosclerosis-journal.com/article/S0021-9150(23)00207-1/fulltext